Long-term Study of CS-3150 as Monotherapy or in Combination With Other Antihypertensive Drug in Japanese Patients With Essential Hypertension

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 368 participants.

Also called NCT02722265

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 368 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02722265
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Japan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02722265. Allocation not applicable; no masking; primary purpose treatment. Start 2016-03 (registry gives no type); primary completion 2017-07-08 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Long-term Study of CS-3150 as Monotherapy or in Combination With Other Antihypertensive Drug in Japanese Patients With Essential Hypertension
Condition
Essential Hypertension
Intervention (Drug)
CS-3150
Lead sponsor
Daiichi Sankyo Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct02722265
Content hash
c015fa2fc7249a8c16d407b2bcbf39a0e497926c9e4bbd471ef71165e4842c46